

Eulália Genescá

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104092/publications.pdf>

Version: 2024-02-01

41
papers

983
citations

623734
14
h-index

434195
31
g-index

43
all docs

43
docs citations

43
times ranked

1639
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. <i>Leukemia and Lymphoma</i> , 2022, 63, 1993-1996.	1.3	2
2	Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets. <i>Cancers</i> , 2022, 14, 1873.	3.7	8
3	Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Cancers</i> , 2022, 14, 2474.	3.7	2
4	Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 5395-5402.	5.2	21
5	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	1.4	48
6	The Yin and Yang-Like Clinical Implications of the CDKN2A/ARF/CDKN2B Gene Cluster in Acute Lymphoblastic Leukemia. <i>Genes</i> , 2021, 12, 79.	2.4	17
7	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. <i>Hematological Oncology</i> , 2021, 39, 529-538.	1.7	3
8	Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021, 109, 106612.	0.8	11
9	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. <i>Blood</i> , 2021, 138, 3486-3486.	1.4	2
10	The evolution of relapse of adult T cell acute lymphoblastic leukemia. <i>Genome Biology</i> , 2020, 21, 284.	8.8	13
11	Who Should Receive an Allogeneic Transplant in First Complete Remission?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S48-S51.	0.4	0
12	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297.	3.5	29
13	Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091963.	2.5	4
14	Genetics and epigenetics of leukemia and lymphoma: from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute. <i>Hematological Oncology</i> , 2020, 38, 432-438.	1.7	6
15	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	2.8	13
16	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e513-e522.	0.4	5
17	Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
18	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Genome-wide identification of microRNA signatures associated with stem/progenitor cells in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Molecular Biology Reports</i> , 2019, 46, 1295-1306.	2.3	3
20	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , 2019, 125, 2810-2817.	4.1	13
21	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	2.5	6
22	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86.	2.2	14
23	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial. <i>Blood</i> , 2019, 134, 826-826.	1.4	10
24	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84.	0.8	9
25	The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 357-368.	2.5	4
26	Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation. <i>Cancer Discovery</i> , 2018, 8, 1614-1631.	9.4	30
27	Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 96.	17.0	19
28	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1739-1751.	4.1	87
29	Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols. <i>Blood</i> , 2018, 132, 1553-1553.	1.4	6
30	Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 810-820.	2.8	21
31	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. <i>Leukemia Research</i> , 2016, 41, 12-20.	0.8	41
32	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5281-5281.	1.4	0
33	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <sc>B</sc> acute lymphoblastic leukemia enrolled in <sc>PETHEMA</sc> protocols. <i>Cancer</i> , 2015, 121, 3809-3817.	4.1	43
34	Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. <i>OncoTargets and Therapy</i> , 2015, 8, 1567.	2.0	37
35	Implications of basic research in clinical practice: toward a personalized medicine in T-cell Acute Lymphoblastic Leukemia (T-ALL). <i>Molecular Biology (Los Angeles, Calif)</i> , 2015, 04, .	0.0	0
36	Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S173-S174.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S174.	0.4	0
38	TREATMENT OF ADOLESCENT AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014052.	1.3	21
39	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. <i>Blood</i> , 2014, 124, 3798-3798.	1.4	0
40	Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group. <i>Blood</i> , 2013, 122, 2556-2556.	1.4	0
41	DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. <i>Human Molecular Genetics</i> , 2000, 9, 1681-1690.	2.9	426